Vanguard Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,040,978 shares of CPRX stock, worth $174 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,040,978
Previous 8,100,355
0.73%
Holding current value
$174 Million
Previous $125 Million
27.4%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$405 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$135 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$123 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$65.4 Million0.01% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.8MShares$60.7 Million0.13% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.23B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...